GlaxoSmithKline said the arrival of a generic competitor would reduce U.S. Advair revenue to around £1 billion in 2017, compared with £1.8 billion in 2016. "GlaxoSmithKline Swung to Profit in Fourth Quarter, Helped by Weak Pound -- Update," at 14:22 GMT, incorrectly stated that the forecast was for all Advair revenue, compared with the 2016 global Advair figure of £3.5 billion.

(END) Dow Jones Newswires

February 08, 2017 11:27 ET (16:27 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.